Author

Liang Xu

h-index 6 View on Semantic Scholar

We have 2 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Targeting the PHB2–ACSL3 Lipid‐Remodeling Axis Overcomes Cisplatin Resistance by Restoring Ferroptosis in Gastric Cancer

A PHB2–ACSL3 lipid‐metabolic axis that drives ferroptosis escape is defined and Mavorixafor repurposing is identified as an immediately translatable strategy to overcome cisplatin resistance in treatment‐refractory GC.

Liang Xu, Wanying Xiang, Xinyue Wang et al. · Advancement of science · 0 citations

Open access Aug 2026

p38β-mediated BiP phosphorylation drives stemness and chemoresistance by suppressing UPR activation in hepatocellular carcinoma

It is discovered that p38β/MAPK11 phosphorylation of BiP promotes stemness and chemoresistance in HCC, revealing a targetable p38β–BiP axis in HCC.

Liang Xu, I. B. Huang, Minghe Zhang et al. · Nature Communications · 0 citations